Marcus from Spain

Registered at the short selling broker Capital, 3 minutes ago.

» Try Capital you too
71.2% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Pfizer Inc. (PFE) shares information

Pfizer Inc.


24h Change

0.71 %

PFE

Live rate: Market closed

Stock data per Monday 10 May, 2021

PFE
NEW YORK STOCK EXCHANGE, INC.
39.58
39.95
39.86
0.28 (+ 0.71%)
US Market is closed

Live Stock price in graph for Pfizer Inc. (PFE)

  • Latest Volume

    30,479,914 (-9.84 %)

  • Volume prev. day

    33,807,757

  • Avg. daily volume

    33,267,294

  • Market cap

    222,324,311,511

  • P/E ratio

    23.31

  • Today high

    40.28 USD

  • Today low

    39.78 USD

  • 52 week high

    42.2 USD

  • 52 week low

    30.35 USD

  • YTD Change

    + 10.47 %

Quick links

 

Latest news about Pfizer Inc.

Below you can find the most recent news posts about Pfizer Inc., primarily from US and UK based news sources.

UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer

Monday, 10 May 2021, 20:48:22
England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE ) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as first-line maintenance therapy for urothelial cancer after platinum-based chemo. The PD-L1 inhibitor, therefore, won’t be able to enjoy routine NHS reimbursement or coverage through the more complicated and restrictive Cancer Drugs Fund, said the National Institute for Health and Care Excellence (NICE). Bavencio showed in the Phase 3 Javelin Bladder 100 trial that it could cut the risk of death by 31% compared with best supportive care when used after one chemo cycle. It … Full story available on Benzinga.com
— Benzinga


Pfizer could sell nearly $100 billion worth of COVID-19 vaccines in the next five years, Morgan Stanley estimates (PFE)

Monday, 10 May 2021, 18:27:53
Summary List Placement Morgan Stanley estimates Pfizer will rake in nearly $100 billion from COVID-19 vaccine sales over the next five years. Pfizer's COVID-19 vaccine will earn about $96.1 billion by 2025, primarily during this year and next when demand for vaccines is the highest, Morgan Stanley said in an analyst note released May 9. Morgan Stanley tripled its prior estimate of $32 billion in revenue for COVID-19 vaccine sales over a four-year span. The bank said its projection is contingent on if the World Trade Organization does not lift vaccine patents, but said the firm will “watch future news.” World leaders, humanitarians, doctors, and other interest groups are pushing President Joe Biden to suspend vaccine patents , by way of a waiver at the World Trade Organization. The move would lift intellectual property rights of pharmaceutical firms and allow drugmakers around the world to replicate the vaccine. Read more: Inside Amazon's and Walmart's bets to transform healthcare as the shopping rivals carve out a new battleground Morgan Stanley's expectations balloons Pfizer's own sales projections.
— Business Insider


Italian woman accidentally given six shots of Covid-19 vaccine

Monday, 10 May 2021, 18:10:31
A 23-year-old woman who was mistakenly given six doses of the Pfizer BioNTech Covid-19 vaccine has been discharged from the hospital where she was being monitored for any adverse reaction.
— CNN


BioNTech Clocked Massive Q1 Revenue Growth; Estimates COVID-19 Vaccine Revenues Of €12B

Monday, 10 May 2021, 14:06:06
BioNTech SE (NASDAQ: BNTX ) reports Q1 FY21 revenues of €2.05 billion compared to €27.7 million a year ago. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. As of May 6, BioNTech and its partner Pfizer Inc (NYSE: PFE ) have shipped approximately 450 million doses of its COVID-19 vaccine (BNT162b2). BioNTech clocked operating income of €1.7 billion, a turnaround from a loss of €59.3 million a year … Full story available on Benzinga.com
— Benzinga


Young Australians with disabilities lose out as Pfizer vaccine is rolled out to under-50s

Monday, 10 May 2021, 10:25:36
Health department acknowledges it is yet to finalise a new plan to vaccinate the priority group Prioritising the Pfizer vaccine for residents under 50 has wrought havoc on Australia’s attempt to vaccinate young people with disabilities living in care homes against Covid. The federal health department has acknowledged it is yet to finalise a new plan to vaccinate the priority group. Continue reading…
— The Guardian


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have PFE available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.